Extension of the date for the presentation of the International Zendal Awards

  • Candidates will have until 10 October to formalise their registration for this first edition.
  • The projects presented will be assessed by an international scientific committee made up of outstanding figures from the fields of health and biotechnology.

Vigo, 1 October 2019. Zendal, a Spanish bio-pharmaceutical group, has extended the call for the 1st edition of the awards bearing the same name, which will recognise the most prestigious and innovative practices in the field of health and biotechnology, giving them international visibility and projection.

The deadline for receipt of applications is 10 October. Applicants must submit their application through an online registration form available on the www.zendal.com website, where the terms and conditions of the awards can also be consulted. This first edition was created with the aim of supporting, distinguishing and promoting knowledge and research in the field of biotechnology worldwide.

The international scientific committee is made up of:

Juan José Badiola Díaz
Professor of Animal Health at the University of Zaragoza, former rector of the University of Zaragoza and former president of the General Council for the Colegios Veterinarios de España (Association of Veterinaries of Spain).

Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices)
A representative of the Agencia Española de Medicamentos y Productos Sanitarios will attend on behalf of the director, María Jesús Lamas.

María Jaureguizar Redondo
Managing Director of the Vet+i-Spanish Animal Health Technology Platform Foundation.

Carlos Martín Montañés
Professor of Microbiology, Preventive Medicine and Public Health and main coordinator of the Mycobacteria Genetics research group at the University of Zaragoza.

Miguel Ángel Llamas
Partner and member of the Board of ComunicaBiotec. Professor of Immunology at the Alfonso X el Sabio University, CEO of the company Empireo diagnóstico molecular.

Jelle Thole
Product and Clinical Development Director for TBVI (Tuberculosis Vaccine Initiative).